Scott Ferguson Sachem Head Capital Management
Scott Ferguson is the founder of Sachem Head Capital Management, an activist and fundamental equity firm. He previously worked at firms including Corvex and built a reputation for research-driven campaigns at public companies. Ferguson’s filings and activist situations are followed closely in event-driven and engagement-oriented investing circles.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PTC
PTC
|
+$88M |
| 2 |
AGN
Allergan plc
AGN
|
+$52.2M |
| 3 |
Air Products & Chemicals
APD
|
+$26.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
|
+$125M |
| 2 |
Viatris
VTRS
|
+$115M |
| 3 |
Bio-Rad Laboratories Class A
BIO
|
+$37.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 45.83% |
| 2 | Healthcare | 34.09% |
| 3 | Materials | 9.64% |
| 4 | Technology | 6.13% |
| 5 | Communication Services | 4.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
CDK
1
DELISTED
CDK Global, Inc.
CDK
| $683M | 45.83% |
12,647,333
| – | – |
2014 Q4
2 quarters
|
|
|
AGN
2
DELISTED
Allergan plc
AGN
| $296M | 19.86% |
975,000
+175,000
| +22% | +$52.2M |
2014 Q3
3 quarters
|
|
3
Zoetis
ZTS
$32.5B
| $212M | 14.23% |
4,395,000
| – | – |
2014 Q1
5 quarters
|
|
|
4
Air Products & Chemicals
APD
$69.2B
| $144M | 9.64% |
1,135,050
+194,580
| +21% | +$26.5M |
2014 Q1
5 quarters
|
|
|
5
PTC
PTC
$21.1B
| $91.3M | 6.13% |
+2,225,000
| New | +$88M |
2015 Q2
0 quarters
|
|
|
TFCFA
6
DELISTED
Twenty-First Century Fox, Inc. Class A
TFCFA
| $64.2M | 4.31% |
1,971,762
| – | – |
2014 Q1
5 quarters
|
|
|
7
Bio-Rad Laboratories Class A
BIO
$10.2B
| – | – |
-280,000
| Closed | -$37.8M | – |
|
|
8
Viatris
VTRS
$22B
| – | – |
-1,945,000
| Closed | -$115M | – |
|
|
SLXP
9
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
| – | – |
-725,000
| Closed | -$125M | – |
|
Similar funds
Scott Ferguson's Q2 2015 Portfolio in Review
As of Q2 2015, Scott Ferguson held 9 positions worth $1.49B, down 1.3% from $1.51B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Scott Ferguson withdrew a net $112M in Q2 2015, closing 3 positions. Its most notable exit was SALIX PHARMACEUTICALS LTD DEL, an estimated $125M position sold in full.
By sector, the portfolio is most concentrated in Industrials at 46% of assets, up from 39% a quarter earlier, followed by Healthcare and Materials.
Against the trend, Scott Ferguson opened a new position in PTC worth $91.3M.
- Scott Ferguson's largest Q2 2015 buy was PTC: 2,225,000 shares worth $91.3M.
- Scott Ferguson added most to Allergan plc in Q2 2015, an estimated $52.2M increase.
- Scott Ferguson fully exited SALIX PHARMACEUTICALS LTD DEL in Q2 2015, selling an estimated $125M.
- Scott Ferguson's ten largest holdings make up 100% of its $1.49B portfolio in Q2 2015.
- Scott Ferguson opened 1 new position and closed 3 in Q2 2015.
- Scott Ferguson's portfolio value fell 1.3% quarter-over-quarter to $1.49B.
Based on Sachem Head Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.